Hyung, Jaewon
Cho, Hyungwoo
Kim, Hyung-Don
Park, Young Soo
Moon, Meesun
Ryu, Min-Hee
Kang, Yoon-Koo http://orcid.org/0000-0003-0783-6583
Article History
Received: 29 July 2023
Accepted: 27 September 2023
First Online: 27 October 2023
Declarations
:
: Conflicts of interest Nothing directly related to this work. Out of this work, YK Kang has served as a consultant for Liscure, ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, and Merck (MSD). MH Ryu received an honorarium and served on the advisory boards of Ono Pharmaceutical, BMS, MSD, Lily, Taiho, Novartis, Daiichi Sankyo, and AstraZeneca, and served as a consultant for DAEHWA Pharmaceutical, BMS, Lily, and Ono Pharmaceutical.